复发转移性宫颈癌的治疗研究进展
Research Progress on the Treatment of Recurrent and Metastatic Cervical Cancer
DOI: 10.12677/jcpm.2024.34373, PDF,   
作者: 马宇倩：承德医学院研究生学院；顾 涛*：秦皇岛市第一医院肿瘤放疗科，河北 秦皇岛
关键词: 复发转移性宫颈癌；治疗进展；放射治疗；全身治疗；Recurrent and Metastatic Cervical Cancer； Treatment Progress； Radiotherapy； Systemic Therapy
摘要: 宫颈癌是全球女性最常见的癌症类型之一，尽管通过标准治疗可达到早期阶段的治愈，获得较长的无病生存期，但仍有部分患者在治疗后期发生复发或转移。然而复发、转移性宫颈癌患者面临着预后差、生存期短等问题，因其既往行手术、放疗或化疗治疗史，故对于复发、转移性宫颈癌的治疗选择方面有一定局限。随着手术、放疗技术的改进和定制治疗方法的采用以及靶向药物、免疫治疗的新兴，为复发、转移性宫颈癌的治疗带来了新方向。现就复发、转移性宫颈癌的治疗研究新进展展开综述。
Abstract: Cervical cancer is one of the most common types of cancer in women worldwide, and although early stage cure with standard treatment provides a long disease-free survival, some patients still develop recurrence or metastasis in the later stage of treatment. However, the patients with recurrent and metastatic cervical cancer are faced with poor prognosis and short survival period, and due to their previous history of surgery, radiotherapy or chemotherapy, the treatment choice of recurrent and metastatic cervical cancer is limited. With the improvement of surgery and radiotherapy technology and the adoption of customized treatment methods and the application of targeted drugs and immune drugs, it brings a new direction for the treatment of recurrent and metastatic cervical cancer. The new progress in the treatment of recurrent and metastatic cervical cancer is reviewed.
文章引用：马宇倩, 顾涛. 复发转移性宫颈癌的治疗研究进展[J]. 临床个性化医学, 2024, 3(4): 2621-2626. https://doi.org/10.12677/jcpm.2024.34373

参考文献

[1] Cohen, P.A., Jhingran, A., Oaknin, A. and Denny, L. (2019) Cervical Cancer. The Lancet, 393, 169-182. [Google Scholar] [CrossRef] [PubMed]
[2] Dornhöfer, N. and Höckel, M. (2008) New Developments in the Surgical Therapy of Cervical Carcinoma. Annals of the New York Academy of Sciences, 1138, 233-252. [Google Scholar] [CrossRef] [PubMed]
[3] Boussios, S., Seraj, E., Zarkavelis, G., Petrakis, D., Kollas, A., Kafantari, A., et al. (2016) Management of Patients with Recurrent/Advanced Cervical Cancer Beyond First Line Platinum Regimens: Where Do We Stand? A Literature Review. Critical Reviews in Oncology/Hematology, 108, 164-174. [Google Scholar] [CrossRef] [PubMed]
[4] 巨宇叶, 张芳芳, 王晓慧. 复发性宫颈癌的治疗现状及进展[J]. 国际妇产科学杂志, 2021, 48(1): 56-60+70.
[5] 周晖, 白守民, 林仲秋. 《2019 NCCN宫颈癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2018, 34(9): 1002-1009.
[6] 白萍, 马莹, 李巍, 等. 子宫颈癌全量放疗后局部肿瘤未控或中心型复发患者的手术治疗[J]. 中华肿瘤杂志, 2010, 32(1): 52-55.
[7] Vigneswaran, H.T., Schwarzman, L.S., Madueke, I.C., David, S.M., Nordenstam, J., Moreira, D., et al. (2020) Morbidity and Mortality of Total Pelvic Exenteration for Malignancy in the Us. Annals of Surgical Oncology, 28, 2790-2800. [Google Scholar] [CrossRef] [PubMed]
[8] 张灿, 张国楠. 盆腔廓清术在原发及复发性宫颈癌中应用的系统评价[J]. 现代妇产科进展, 2020, 29(2): 92-97.
[9] 彭莛婷, 唐均英. 复发性宫颈癌治疗策略研究进展[J]. 现代医药卫生, 2020, 36(21): 3446-3450.
[10] Kim, H.J., Chang, J.S., Koom, W.S., Lee, K.C., Kim, G.E. and Kim, Y.B. (2018) Radiotherapy Is a Safe and Effective Salvage Treatment for Recurrent Cervical Cancer. Gynecologic Oncology, 151, 208-214. [Google Scholar] [CrossRef] [PubMed]
[11] Llewelyn, M. and Taylor, A. (2017) Re-Irradiation of Cervical and Endometrial Cancer. Current Opinion in Oncology, 29, 343-350. [Google Scholar] [CrossRef] [PubMed]
[12] Sadozye, A.H. (2018) Re-Irradiation in Gynaecological Malignancies: A Review. Clinical Oncology, 30, 110-115. [Google Scholar] [CrossRef] [PubMed]
[13] Adeberg, S., Harrabi, S.B., Bougatf, N., Verma, V., Windisch, P., Bernhardt, D., et al. (2018) Dosimetric Comparison of Proton Radiation Therapy, Volumetric Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy Based on Intracranial Tumor Location. Cancers, 10, Article No. 401. [Google Scholar] [CrossRef] [PubMed]
[14] Lin, Y., Ouyang, Y., Chen, K., Lu, Z., Liu, Y. and Cao, X. (2019) Clinical Outcomes of Volumetric Modulated Arc Therapy Following Intracavitary/Interstitial Brachytherapy in Cervical Cancer: A Single Institution Retrospective Experience. Frontiers in Oncology, 9, Article No. 760. [Google Scholar] [CrossRef] [PubMed]
[15] Bockel, S., Espenel, S., Sun, R., Dumas, I., Gouy, S., Morice, P., et al. (2021) Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review. Cancers, 13, Article No. 1226. [Google Scholar] [CrossRef] [PubMed]
[16] Shen, Z., Qu, A., Jiang, P., Jiang, Y., Sun, H. and Wang, J. (2022) Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review. Current Oncology, 29, 5262-5277. [Google Scholar] [CrossRef] [PubMed]
[17] Umezawa, R., Murakami, N., Nakamura, S., Wakita, A., Okamoto, H., Tsuchida, K., et al. (2018) Image-Guided Interstitial High-Dose-Rate Brachytherapy for Locally Recurrent Uterine Cervical Cancer: A Single-Institution Study. Brachytherapy, 17, 368-376. [Google Scholar] [CrossRef] [PubMed]
[18] 郑丹, 袁志平, 林川, 等. 125I粒子植入治疗宫颈癌放化疗后照射野内复发患者的临床疗效[J]. 实用临床医药杂志, 2015, 19(21): 77-81.
[19] Liu, Y., Jiang, P., Zhang, H. and Wang, J. (2021) Safety and Efficacy of 3d-Printed Templates Assisted CT-Guided Radioactive Iodine-125 Seed Implantation for the Treatment of Recurrent Cervical Carcinoma after External Beam Radiotherapy. Journal of Gynecologic Oncology, 32, e15. [Google Scholar] [CrossRef] [PubMed]
[20] Biete, A. and Oses, G. (2018) Intraoperative Radiation Therapy in Uterine Cervical Cancer: A Review. Reports of Practical Oncology & Radiotherapy, 23, 589-594. [Google Scholar] [CrossRef] [PubMed]
[21] Tewari, K.S., Sill, M.W., Long, H.J., Penson, R.T., Huang, H., Ramondetta, L.M., et al. (2014) Improved Survival with Bevacizumab in Advanced Cervical Cancer. New England Journal of Medicine, 370, 734-743. [Google Scholar] [CrossRef] [PubMed]
[22] Monk, B.J., Sill, M.W., McMeekin, D.S., Cohn, D.E., Ramondetta, L.M., Boardman, C.H., et al. (2009) Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 27, 4649-4655. [Google Scholar] [CrossRef] [PubMed]
[23] Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., et al. (2024) Pembrolizumab or Placebo with Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomised, Double-Blind, Phase 3 Clinical Trial. The Lancet, 403, 1341-1350. [Google Scholar] [CrossRef] [PubMed]
[24] Monk, B.J., Colombo, N., Tewari, K.S., Dubot, C., Caceres, M.V., Hasegawa, K., et al. (2023) First-Line Pembrolizumab + Chemotherapy versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of Keynote-826. Journal of Clinical Oncology, 41, 5505-5511. [Google Scholar] [CrossRef] [PubMed]
[25] Tewari, K.S., Colombo, N., Monk, B.J., Dubot, C., Cáceres, M.V., Hasegawa, K., et al. (2024) Pembrolizumab or Placebo plus Chemotherapy with or without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial. JAMA Oncology, 10, 185-192. [Google Scholar] [CrossRef] [PubMed]
[26] 周晖, 刘昀昀, 罗铭, 等. 《2023 NCCN子宫颈癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2023, 39(2): 189-196.
[27] Gao, X., Xu, N., Li, Z., Shen, L., Ji, K., Zheng, Z., et al. (2023) Safety and Antitumour Activity of Cadonilimab, an Anti-Pd-1/ctla-4 Bispecific Antibody, for Patients with Advanced Solid Tumours (COMPASSION-03): A Multicentre, Open-Label, Phase 1b/2 Trial. The Lancet Oncology, 24, 1134-1146. [Google Scholar] [CrossRef] [PubMed]
[28] McNamara, B., Greenman, M., Pebley, N., Mutlu, L. and Santin, A.D. (2023) Antibody-Drug Conjugates (ADC) in Her2/Neu-Positive Gynecologic Tumors. Molecules, 28, Article No. 7389. [Google Scholar] [CrossRef] [PubMed]
[29] 夏玲芳, 朱俊, 吴小华. 2023年ESMO妇科肿瘤治疗最新进展及展望[J]. 中国癌症杂志, 2023, 33(11): 969-980.
[30] Heitz, N., Greer, S.C. and Halford, Z. (2022) A Review of Tisotumab Vedotin-TFTV in Recurrent or Metastatic Cervical Cancer. Annals of Pharmacotherapy, 57, 585-596. [Google Scholar] [CrossRef] [PubMed]
[31] Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D., Banerjee, S., González-Martín, A., et al. (2024) Efficacy and Safety of Trastuzumab Deruxtecan in Patients with Her2-Expressing Solid Tumors: Primary Results from the Destiny-Pantumor02 Phase II Trial. Journal of Clinical Oncology, 42, 47-58. [Google Scholar] [CrossRef] [PubMed]
[32] 谢玲玲, 林仲秋. 《2024 NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2023, 39(11): 1122-1127.
[33] García, E., Ayoub, N. and Tewari, K.S. (2024) Recent Breakthroughs in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer. Journal of Gynecologic Oncology, 35, e30. [Google Scholar] [CrossRef] [PubMed]
[34] Méndez-Valdés, G., Gómez-Hevia, F., Lillo-Moya, J., González-Fernández, T., Abelli, J., Cereceda-Cornejo, A., et al. (2023) Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-Vegf Monoclonal Antibodies. Biomedicines, 11, Article No. 718. [Google Scholar] [CrossRef] [PubMed]
[35] Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L.P., Di Napoli, M., et al. (2019) PARP Inhibitors in Ovarian Cancer. Cancer Treatment Reviews, 73, 1-9. [Google Scholar] [CrossRef] [PubMed]
[36] Nakai, H. and Matsumura, N. (2023) Selection of Maintenance Therapy during First-Line Treatment of Advanced Ovarian Cancer Based on Pharmacologic Characteristics. Expert Opinion on Pharmacotherapy, 24, 2161-2173. [Google Scholar] [CrossRef] [PubMed]
[37] Mauricio, D., Zeybek, B., Tymon-Rosario, J., Harold, J. and Santin, A.D. (2021) Immunotherapy in Cervical Cancer. Current Oncology Reports, 23, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[38] Vergote, I., Van Nieuwenhuysen, E., Casado, A., Laenen, A., Lorusso, D., Braicu, E.I., et al. (2023) Randomized Phase II BGOG/ENGOT-cx1 Study of Paclitaxel-Carboplatin with or without Nintedanib in First-Line Recurrent or Advanced Cervical Cancer. Gynecologic Oncology, 174, 80-88. [Google Scholar] [CrossRef] [PubMed]
[39] 徐红, 张静. 美国国立综合癌症网络《2020年宫颈癌临床实践指南》病理内容更新解读[J]. 中华病理学杂志, 2021, 50(1): 9-13.